Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies

被引：32
作者：
Chiricozzi, Andrea [1 ,2 ]
Gisondi, Paolo [3 ]
Bellinato, Francesco [3 ]
Girolomoni, Giampiero [3 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dermatol, I-00168 Rome, Italy
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, I-37129 Verona, Italy
来源：
VACCINES | 2020年 / 8卷 / 04期
关键词：
psoriasis; vaccination; vaccine; biologics; methotrexate; cyclosporine; apremilast; dimethyl fumarate; RHEUMATOID-ARTHRITIS; INFLUENZA VACCINATION; PNEUMOCOCCAL VACCINE; ANTIBODY-RESPONSE; ADULT PATIENTS; METHOTREXATE; TETANUS; MODERATE; CYCLOSPORINE; SUPPRESSION;
D O I：
10.3390/vaccines8040769
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Psoriasis is a chronic inflammatory skin disease usually treated with immunomodulatory/immunosuppressive agents. The use of these agents has been associated with an increased susceptibility to infections. Vaccination might represent a critical aspect in the management of patients with psoriasis treated with immunomodulatory/immunosuppressive therapies. This narrative review aimed to provide an overview on the immune response to vaccines in subjects treated with systemic agents used to treat patients with moderate to severe psoriasis. Publications appearing in PubMed, Scopus, and ISI-Web of Knowledge database were selected using Medical Subject Headings key terms. Overall, published data confirmed that vaccination with attenuated live vaccines during therapy with immunomodulatory/immunosuppressive therapies should be avoided. For nonlive vaccines, a more favorable safety profile of biologic agents compared to conventional systemic agents is described as the humoral response to vaccines is in general well-preserved. Treatment with cyclosporine and methotrexate is associated with lower antibody titers to vaccines, and thus these agents are better discontinued during vaccination. In contrast, treatment with biological agents is not associated with lower antibody response and can thus be continued safely.
引用
收藏
页码：1 / 12
页数：12
相关论文
共 49 条
[1]   COVID-19 and mRNA Vaccines-First Large Test for a New Approach [J].
Abbasi, Jennifer .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (12) :1125-1127
[2]   Vaccination status of patients using anti-TNF therapy and the physicians' behavior shaping the phenomenon: Mixed-methods approach [J].
Al-Omar, Hussain Abdulrahman ;
Sherif, Hadeel Magdy ;
Mayet, Ahmed Yaccob .
PLOS ONE, 2019, 14 (10)
[3]   Vaccination under TNF blockade - less effective, but worthwhile [J].
Aringer, Martin .
ARTHRITIS RESEARCH & THERAPY, 2012, 14 (03)
[4]  
Brodmerkel C, 2013, J DRUGS DERMATOL, V12, P1122
[5]   Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study [J].
Chioato, A. ;
Noseda, E. ;
Stevens, M. ;
Gaitatzis, N. ;
Kleinschmidt, A. ;
Picaud, H. .
CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (10) :1597-1602
[6]   Fundamentals of Vaccine Immunology [J].
Clem, Angela S. .
JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2011, 3 (01) :73-78
[7]   Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry [J].
Davila-Seijo, Paula ;
Dauden, Esteban ;
Descalzo, M. A. ;
Carretero, Gregorio ;
Carrascosa, Jose-Manuel ;
Vanaclocha, Francisco ;
Gomez-Garcia, Francisco-Jose ;
de la Cueva-Dobao, Pablo ;
Herrera-Ceballos, Enrique ;
Belinchon, Isabel ;
Lopez-Estebaranz, Jose-Luis ;
Alsina, Merce ;
Sanchez-Carazo, Jose-Luis ;
Ferran, Marta ;
Torrado, Rosa ;
Ferrandiz, Carlos ;
Rivera, Raquel ;
Llamas, Mar ;
Jimenez-Puya, Rafael ;
Garcia-Doval, Ignacio .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (02) :313-321
[8]  
Dudelzak J, 2008, J DRUGS DERMATOL, V7, P684
[9]   Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus [J].
Elkayam, O ;
Paran, D ;
Caspi, D ;
Litinsky, I ;
Yaron, M ;
Charboneau, D ;
Rubins, JB .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) :147-153
[10]   Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors [J].
Fuchs, Inbal ;
Avnon, Lone ;
Freud, Tamar ;
Abu-Shakra, Mahmoud .
CLINICAL RHEUMATOLOGY, 2009, 28 (02) :167-172
12345